Hims & Hers Health, Inc. (NYSE:HIMS) Chief Commercial Officer, Michael Chi, has recently engaged in significant stock transactions, according to the latest SEC filings. On July 23rd and 24th, Chi sold a total of 24,803 shares of Class A Common Stock in the telehealth company, netting $549,991. The sale prices ranged between $22.00 and $22.25 per share.
In addition to the sales, the filings also show that Chi acquired shares through the exercise of stock options on the same dates. On July 23rd, he exercised options to buy 7,500 shares at $13.90 each, and on July 24th, another 17,303 shares at $5.01 each, totaling an investment of $190,938. These transactions were executed under a Rule 10b5-1 trading plan, which was adopted on March 1, 2024.
The executed stock options are part of a service-based vesting requirement, with some vesting monthly since as early as March 24, 2022. The footnotes in the SEC filing indicate that these stock options are set to vest over a four-year period, with specific vesting milestones outlined for the shares.
Hims & Hers Health, known for its direct-to-consumer wellness and healthcare products, has been a subject of investor interest as the telehealth market continues to expand. The transactions by a high-ranking executive such as Chi could be of note to investors tracking insider activity as an indicator of the company's performance and outlook.
Investors and followers of Hims & Hers Health will be keeping a close eye on the company's stock, which trades under the ticker symbol HIMS on the New York Stock Exchange.
In other recent news, Hims & Hers Health, Inc. has announced the appointment of Kåre Schultz as a new independent director, expanding its board from eight to nine directors. This strategic addition is expected to provide valuable insights and guidance to the company as it continues to grow in the telehealth industry. On the earnings front, Hims & Hers Health is anticipated to exceed revenue estimates by approximately $15 million for the second quarter of 2024, according to Truist Securities.
Several financial firms have also adjusted their price targets for the company. Truist Securities revised its price target to $23.00, while TD Cowen and BofA Securities raised their targets to $25 and $26 respectively. However, Citi downgraded the company from Buy to Neutral, despite raising the price target to $20, due to potential regulatory risks associated with the GLP-1 launch.
In the analysts' view, the company's future performance will depend on the successful expansion of its weight loss program and the management of potential regulatory risks. These developments underscore the importance of the company's expansion into GLP-1 treatment for weight loss and its impact on the company's stock targets.
InvestingPro Insights
As Hims & Hers Health, Inc. (NYSE:HIMS) navigates the expanding telehealth market, recent transactions by Chief Commercial Officer Michael Chi have put a spotlight on the company's financial dynamics. In light of these developments, let's delve into some key metrics and insights from InvestingPro that may interest investors.
InvestingPro data indicates a robust revenue growth for Hims & Hers, with an impressive 55.65% increase in the last twelve months as of Q1 2024. This is further bolstered by a quarterly revenue growth of 45.81% in Q1 2024, reflecting the company's strong performance in the increasingly competitive telehealth sector. Despite facing challenges common in growth-focused companies, such as an operating income margin of -0.54%, Hims & Hers has managed to maintain a gross profit margin of 82.41%, showcasing its ability to generate substantial gross profits from its revenues.
InvestingPro Tips highlight that Hims & Hers is expected to see net income growth this year, with analysts predicting the company will turn profitable. This optimism is supported by the fact that three analysts have recently revised their earnings upwards for the upcoming period. Additionally, the company has experienced a significant return over the last week, with a 10.51% price total return, which could be indicative of positive investor sentiment.
For investors looking to delve deeper into the financial health and future prospects of Hims & Hers Health, additional insights are available on InvestingPro, where there are 13 more InvestingPro Tips that can help in making a well-informed decision. To access these insights, visit: https://www.investing.com/pro/HIMS. Don't forget to use the coupon code PRONEWS24 to get up to 10% off a yearly Pro and a yearly or biyearly Pro+ subscription, offering a valuable resource for those tracking the performance of Hims & Hers Health, Inc.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.